Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study
PLOS Medicine · 16.04.2026 · 23 (4) · e1005047
DOI: 10.1371/journal.pmed.1005047 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS Medicine, online erschienen am 16.04.2026. Verfasst von Yifan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Antidepressive Agents, Ketamine, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Grants Committee.
Themen: Depression
Abstract (Originalsprache)
Background
Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of esketamine versus multiple alternative third-line strategies for TRD from the Hong Kong healthcare payer’s perspective. Methods and findings A Markov cohort model simulated adults with TRD in Hong Kong over 5 years with 4-week cycles. The model compared esketamine plus AD with six alternative third-line treatment strategies: combination therapy (AD plus AD), augmentation therapy (AD plus antipsychotic or lithium), psychotherapy alone, psychotherapy plus AD, repetitive transcranial magnetic stimulation (rTMS) plus AD, and electroconvulsive therapy (ECT) plus AD. Primary outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) under a US$50,000/QALY willingness-to-pay (WTP) threshold. Deterministic and probabilistic sensitivity analyses and scenario analyses were conducted, focusing on alternative esketamine dosing, delivery strategies, and comparisons with other treatment options to assess the robustness of the results. In base-case analysis, esketamine was not cost-effective versus augmentation, combination, psychotherapy, or psychotherapy plus AD with ICERs ranging from US$134,127 to US$312,750 per QALY but was more cost-effective than rTMS (dominated) and ECT (ICER: US$322,407/QALY). Combination therapy was the most cost-effective among all strategies evaluated. The main limitation of this study is the reliance on indirect comparisons and assumptions derived from heterogeneous clinical trial populations, which may not fully reflect real-world patient characteristics and treatment pathways.
Conclusions
Esketamine appeared more cost-effective than rTMS and ECT, but not cost-effective compared with other commonly used third-line treatment strategies for TRD. These findings suggest that cost-effectiveness evidence may help inform more context-sensitive treatment sequencing strategies beyond conventional line-of-therapy frameworks. Policy approaches such as price negotiation, optimized service delivery, and alternative dosing strategies may improve the value of esketamine for TRD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Department of Global and Environmental Health, School of Global Public Health, New York University, New York, New York, United States of America.
- Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Hong Kong SAR, China.
ORCID-Profile: Yifan Li, Vivien Kin Yi Chan, Mark Jit, Franco Wing Tak Cheng, Dawn Craig, Esther Wai Yin Chan, Xue Li
Förderung
- University Grants Committee
Zitieren
APA
Li, Y., Chan, V. K. Y., Jit, M., Cheng, F. W. T., Yiu, H. H. E., Bishai, D. M., Craig, D., Chan, E. W. Y., Chan, S. S. M., & Li, X. (2026). Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study. PLOS Medicine, 23(4), e1005047. https://doi.org/10.1371/journal.pmed.1005047
Vancouver
Li Y, Chan VKY, Jit M, Cheng FWT, Yiu HHE, Bishai DM, et al. Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study. PLOS Medicine. 2026;23(4):e1005047. doi:10.1371/journal.pmed.1005047
BibTeX
@article{Li2026,
author = {Li, Yifan and Chan, Vivien Kin Yi and Jit, Mark and Cheng, Franco Wing Tak and Yiu, Hei Hang Edmund and Bishai, David Makram and Craig, Dawn and Chan, Esther Wai Yin and Chan, Sandra Sau Man and Li, Xue},
title = {Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {4},
pages = {e1005047},
doi = {10.1371/journal.pmed.1005047}
}
EUVIMED